The Canadian Clinical Trials Asset Map (CCTAM) is an initiative to create an online, searchable database of Canadian clinical research capabilities. The objectives are to improve capacity for clinical research in Canada and position Canada as an attractive destination for clinical trials. Significant progress has been made in developing CCTAM, which will leverage existing asset maps and include comprehensive data on investigators, sites, and research organizations. Once complete, CCTAM aims to be a one-stop tool to support clinical research planning in Canada.
Patientory and its Role in Clinical Trials TransparencyPatientory
Patientory.com. Discover how Patientory as SaaS (Software as a Service) can overcome the challenges of clinical trials transparency and recruitment.
Your Health, at your fingertips. Visit Now Patientory.com.
Accelerating Patient Care with Real World EvidenceCitiusTech
Life sciences and pharma companies are evolving their strategies to utilize Real World Data (RWD) to demonstrate value of pharmaceutical and medical device innovations. Technology advancements at the point of care and improvements in data collection strategies have led to a significant increase in the availability of RWD in healthcare
Real World Evidence (RWE) can provide actionable patient insights and accelerates time to market of new medical products in order to gain competitive advantage
With the emergence of wearable technologies, Internet of Things (IOT), Cognitive Computing, Genomics, Blockchain, etc., future RWE data sources will become more diverse and extensive. This document introduces the concept of Real World Evidence studies in healthcare, describes the various data sources for performing real world analytics and illustrates the role of RWE in better patient care. It then summarizes challenges faced while performing RWE analytics with respect to regulatory compliance, data accessibility and sharing, analysis reporting, costs etc.
Free medicines are available through the pharmaceutical companies’ Patient Assistance Programs (PAPs), which may be accessed for individual prescriptions using The Pharmacy Connection (TPC) software or through a bulk replacement / Institutional PAP. Learn about Rx Partnership, Virginia’s innovative bulk replacement program.
These slides use concepts from my (Jeff Funk) course on Business Models at National University of Singapore to analyze the business model for Theranos. Theranos provides diagnostic testing for consumers that is faster and cheaper than the existing system. Its tests are done in easy to access pharmacies (e.g., Walgreens) as opposed to hard-to reach doctors’ offices. The tests use small bio-electronic integrated circuits (ICs) instead of large scientific instruments. These ICs utilize micro-fluidic channels that require a pin-prick of blood instead of a vial of blood, which makes the tests more appealing and faster than the traditional tests. The slides describe the value proposition, method of value capture, customers, scope of activities, and method of strategic control for Theranos.
Patientory and its Role in Clinical Trials TransparencyPatientory
Patientory.com. Discover how Patientory as SaaS (Software as a Service) can overcome the challenges of clinical trials transparency and recruitment.
Your Health, at your fingertips. Visit Now Patientory.com.
Accelerating Patient Care with Real World EvidenceCitiusTech
Life sciences and pharma companies are evolving their strategies to utilize Real World Data (RWD) to demonstrate value of pharmaceutical and medical device innovations. Technology advancements at the point of care and improvements in data collection strategies have led to a significant increase in the availability of RWD in healthcare
Real World Evidence (RWE) can provide actionable patient insights and accelerates time to market of new medical products in order to gain competitive advantage
With the emergence of wearable technologies, Internet of Things (IOT), Cognitive Computing, Genomics, Blockchain, etc., future RWE data sources will become more diverse and extensive. This document introduces the concept of Real World Evidence studies in healthcare, describes the various data sources for performing real world analytics and illustrates the role of RWE in better patient care. It then summarizes challenges faced while performing RWE analytics with respect to regulatory compliance, data accessibility and sharing, analysis reporting, costs etc.
Free medicines are available through the pharmaceutical companies’ Patient Assistance Programs (PAPs), which may be accessed for individual prescriptions using The Pharmacy Connection (TPC) software or through a bulk replacement / Institutional PAP. Learn about Rx Partnership, Virginia’s innovative bulk replacement program.
These slides use concepts from my (Jeff Funk) course on Business Models at National University of Singapore to analyze the business model for Theranos. Theranos provides diagnostic testing for consumers that is faster and cheaper than the existing system. Its tests are done in easy to access pharmacies (e.g., Walgreens) as opposed to hard-to reach doctors’ offices. The tests use small bio-electronic integrated circuits (ICs) instead of large scientific instruments. These ICs utilize micro-fluidic channels that require a pin-prick of blood instead of a vial of blood, which makes the tests more appealing and faster than the traditional tests. The slides describe the value proposition, method of value capture, customers, scope of activities, and method of strategic control for Theranos.
From Edge Case to Main Case, Michelle Longmire of Medable_mHealth IsraelLevi Shapiro
Presentation by Michelle Longmire, CEO of Medable, April 20, 2021, for mHealth Israel. During CoVID, as physical access to clinics was limited, Medable enabled patients to continue participating in critical research efforts. Medable Supporting over 100 Studies Across a Diverse Array of Therapeutic Areas. Medable provides a platform for seamless evidence
generation, across the entire patient journey. Connecting patients globally for community, care, and research. Improve patient experience and retention. Reduce site burden. Data Cloud & Platform should be flexible and modular to enable protocol-fit digital. Medable Digitome, for data driven decentralized trials and a new era of understanding patients, therapies, and conditions. Clinical research is a small component of the broader healthcare journey. Enable health data and evidence generation from clinical to commercial, from day one. Continuous health data & evidence from clinical to commercial and beyond. The Digitome can provide a
primary observational protocol that collects large scale baseline data in a framework that enables streamlined recruitment, enrollment, and participation into interventional clinical substudies.
mHealth Israel_Becton Dickinson_US Healthcare Digital Transformation_July 2015Levi Shapiro
Presentation for mHealth Israel by David Fegygin, VP of Health IT Integration and Strategic Innovation, Becton Dickinson, for mHealth Israel, July 14, 2015 in Tel Aviv
January 23, 2017
The Fifth Annual Health Law Year in P/Review symposium featured leading experts discussing major developments during 2016 and what to watch out for in 2017. The discussion at this day-long event covered hot topics in such areas as health policy under the new administration, regulatory issues in clinical research, law at the end-of-life, patient rights and advocacy, pharmaceutical policy, reproductive health, and public health law.
The Fifth Annual Health Law Year in P/Review was sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Harvard Health Publications at Harvard Medical School, Health Affairs, the Hastings Center, the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital, and the Center for Bioethics at Harvard Medical School, with support from the Oswald DeN. Cammann Fund.
Learn more on our website: http://petrieflom.law.harvard.edu/events/details/5th-annual-health-law-year-in-p-review
These slides use concepts from my (Jeff Funk) course entitled Biz Models for Hi-Tech Products to analyze the business model for Vishuo Biomedical, a Singaporean startup. This startup offers a data analytics bioinformatics platform that includes an integrated drug-gene-relation database and this platform is constantly updated as scientific advances are reported in academic journals. The platform analyzes genetic sequence data and provides visualization and reports for hospitals. Vishuo targets hospitals and research institutes with DNA sequencers but who need data analytic tools to interpret the DNA sequencing output. The slides summarize the business model for Vishuo including the value proposition, customers, method of value capture, scope of activities, and method of strategic control.
Health Datapalooza IV: June 3rd-4th, 2013
Datalab
Moderator:
Todd Park, Chief Technology Officer, United States
Damon Davis, Health Data Initiative Program Director, Department of Health and Human Services
Speakers:
Susan Queen, Director, Division of Data Policy, Office of the Assistant Secretary for Planning and Evaluation
Steve Cohen, Director, Center for Financing, Access and Cost Trends, Agency for Healthcare Research & Quality
Rick Moser, National Institutes of Health
Victor Lazzaro, Performance & Data Analytics Manager, Office of the National Coordinator for Health IT
Niall Brennan, Director of the Office of Information Products and Data Analytics, Center for Medicare and Medicaid Services
Miya Cain, Office of the Assistant Secretary, Administration for Children and Families, US Department of Health and Human Services
Edward Salsberg, Director, National Center for Health Workforce Analysis, Health Resources and Services Administration
Robert Post, Environmental Protection Agency (EPA)
Eugene Hayes, the Substance Abuse and Mental Health Services Administration (SAMHSA)
Jim Craver, Center for Disease Control and Prevention (CDC)
David Forrest, Senior Advisor, Health and Human Services Office of the Chief Technology Officer
Tania Allard, Director of Intergovernmental Affairs & Special Projects, New York State Department of Health
Steven Edwards, Environmental Protection Agency
Steve Emrick, National Library of Medicine
Carol A. Gotway Crawford, Director of Behavioral Surveillance, Centers for Disease Control
This perennial favorite breakout session is back! This is the best opportunity to meet some of the federal government data experts who champion action in improving public access to information to catalyze innovation. Come learn how to use assets from the Department of Health & Human Services (HHS), the Department of Agriculture (USDA), the Environmental Protection Agency (EPA) and more. Each agency in the federal government is staffed by experts who are well versed in the information resources available from their division on data.gov (administrative data, survey data, research data, medical/scientific content, etc.) The Datalab will also feature opportunities for one-on-one meet-ups with data experts for “deep dives” into agency’s resources. Participants can join live demonstrations and check out new data resources and tools. The goal of the session is to give innovators and entrepreneurs an overview of new, updated, and emerging datasets that can be used to support new applications and services.
Strand featured in CIO Review: Pharma and Life Science Special edition - July 2014
Strand Genomics Inc recognised by CIO Review as one among 20 most promising Tech solution providers to Pharma and Life science industry 2014
Real-world Evidence A Saudi Regulatory PerspectiveUN SPHS
By Mr. Turki A. Al-Thunian, Bpharm, MClinPharm, MSc.Epi, PhD, Acting Director of the Research Informatics Department, Saudi Food and Drug Authority (SFDA), delivered at the Global Forum 2020 Drug Safety and Supply Chains session.
From Edge Case to Main Case, Michelle Longmire of Medable_mHealth IsraelLevi Shapiro
Presentation by Michelle Longmire, CEO of Medable, April 20, 2021, for mHealth Israel. During CoVID, as physical access to clinics was limited, Medable enabled patients to continue participating in critical research efforts. Medable Supporting over 100 Studies Across a Diverse Array of Therapeutic Areas. Medable provides a platform for seamless evidence
generation, across the entire patient journey. Connecting patients globally for community, care, and research. Improve patient experience and retention. Reduce site burden. Data Cloud & Platform should be flexible and modular to enable protocol-fit digital. Medable Digitome, for data driven decentralized trials and a new era of understanding patients, therapies, and conditions. Clinical research is a small component of the broader healthcare journey. Enable health data and evidence generation from clinical to commercial, from day one. Continuous health data & evidence from clinical to commercial and beyond. The Digitome can provide a
primary observational protocol that collects large scale baseline data in a framework that enables streamlined recruitment, enrollment, and participation into interventional clinical substudies.
mHealth Israel_Becton Dickinson_US Healthcare Digital Transformation_July 2015Levi Shapiro
Presentation for mHealth Israel by David Fegygin, VP of Health IT Integration and Strategic Innovation, Becton Dickinson, for mHealth Israel, July 14, 2015 in Tel Aviv
January 23, 2017
The Fifth Annual Health Law Year in P/Review symposium featured leading experts discussing major developments during 2016 and what to watch out for in 2017. The discussion at this day-long event covered hot topics in such areas as health policy under the new administration, regulatory issues in clinical research, law at the end-of-life, patient rights and advocacy, pharmaceutical policy, reproductive health, and public health law.
The Fifth Annual Health Law Year in P/Review was sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Harvard Health Publications at Harvard Medical School, Health Affairs, the Hastings Center, the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital, and the Center for Bioethics at Harvard Medical School, with support from the Oswald DeN. Cammann Fund.
Learn more on our website: http://petrieflom.law.harvard.edu/events/details/5th-annual-health-law-year-in-p-review
These slides use concepts from my (Jeff Funk) course entitled Biz Models for Hi-Tech Products to analyze the business model for Vishuo Biomedical, a Singaporean startup. This startup offers a data analytics bioinformatics platform that includes an integrated drug-gene-relation database and this platform is constantly updated as scientific advances are reported in academic journals. The platform analyzes genetic sequence data and provides visualization and reports for hospitals. Vishuo targets hospitals and research institutes with DNA sequencers but who need data analytic tools to interpret the DNA sequencing output. The slides summarize the business model for Vishuo including the value proposition, customers, method of value capture, scope of activities, and method of strategic control.
Health Datapalooza IV: June 3rd-4th, 2013
Datalab
Moderator:
Todd Park, Chief Technology Officer, United States
Damon Davis, Health Data Initiative Program Director, Department of Health and Human Services
Speakers:
Susan Queen, Director, Division of Data Policy, Office of the Assistant Secretary for Planning and Evaluation
Steve Cohen, Director, Center for Financing, Access and Cost Trends, Agency for Healthcare Research & Quality
Rick Moser, National Institutes of Health
Victor Lazzaro, Performance & Data Analytics Manager, Office of the National Coordinator for Health IT
Niall Brennan, Director of the Office of Information Products and Data Analytics, Center for Medicare and Medicaid Services
Miya Cain, Office of the Assistant Secretary, Administration for Children and Families, US Department of Health and Human Services
Edward Salsberg, Director, National Center for Health Workforce Analysis, Health Resources and Services Administration
Robert Post, Environmental Protection Agency (EPA)
Eugene Hayes, the Substance Abuse and Mental Health Services Administration (SAMHSA)
Jim Craver, Center for Disease Control and Prevention (CDC)
David Forrest, Senior Advisor, Health and Human Services Office of the Chief Technology Officer
Tania Allard, Director of Intergovernmental Affairs & Special Projects, New York State Department of Health
Steven Edwards, Environmental Protection Agency
Steve Emrick, National Library of Medicine
Carol A. Gotway Crawford, Director of Behavioral Surveillance, Centers for Disease Control
This perennial favorite breakout session is back! This is the best opportunity to meet some of the federal government data experts who champion action in improving public access to information to catalyze innovation. Come learn how to use assets from the Department of Health & Human Services (HHS), the Department of Agriculture (USDA), the Environmental Protection Agency (EPA) and more. Each agency in the federal government is staffed by experts who are well versed in the information resources available from their division on data.gov (administrative data, survey data, research data, medical/scientific content, etc.) The Datalab will also feature opportunities for one-on-one meet-ups with data experts for “deep dives” into agency’s resources. Participants can join live demonstrations and check out new data resources and tools. The goal of the session is to give innovators and entrepreneurs an overview of new, updated, and emerging datasets that can be used to support new applications and services.
Strand featured in CIO Review: Pharma and Life Science Special edition - July 2014
Strand Genomics Inc recognised by CIO Review as one among 20 most promising Tech solution providers to Pharma and Life science industry 2014
Real-world Evidence A Saudi Regulatory PerspectiveUN SPHS
By Mr. Turki A. Al-Thunian, Bpharm, MClinPharm, MSc.Epi, PhD, Acting Director of the Research Informatics Department, Saudi Food and Drug Authority (SFDA), delivered at the Global Forum 2020 Drug Safety and Supply Chains session.
From June 2014 presentation by Michael Warden, Johmarx Patton, and Kathleen Ludewig Omollo of University of Michigan Medical School Information Services to their colleagues in the department.
Drawing upon the concept of "permanent white water," the presenters explore the constant change and churn that affects academic medical centers such as UMMS and tactics for how to thrive in such an environment. The presenters highlight trends and models within the education, research, and clinical domains.
Downloadable versions in PPTX and PDF are available at http://open.umich.edu/node/9706/.
Anthony Presentation at DIA Chicago Oct 2008AKTaylor
The requirements of the clinical trial databases provision in the FDA
Amendments Act apply to academic and independent investigators
as well as to industry conducted clinical trials. This session will
highlight the challenges faced by academic and independent investigators
and best practices in registering clinical trials and establishing
procedures for reporting study results to ClinicalTrials.gov.
Borislav Borissov, Former Head of BDA
Presentation at EIPG – BIPA Symposium “Clinical Trials Research” at the Faculty of Pharmacy, Medical University of Sofia, Sofia 2014.
Key Compliance Issues In Clinical Research: What Sites, CROs, and Start-Ups N...Polsinelli PC
Clinical research presents a host of potential compliance and legal risks. This webinar will provide an overview of key legal issues in clinical research applicable to all involved parties, including sponsors, sites and CROs. We will also review recent enforcement activities related to research studies, and provide strategies for addressing issues that arise, both preemptively (through compliance plans) and in response to identified concerns.
Our agenda:
• Understand key rules and regulations and how they apply in the context of clinical research
• Review key areas of compliance risk, ranging from Medicare reimbursement and billing concerns to informed consent and use of equipment and materials in clinical research
• Outline key components of compliance plans and specifics relevant to clinical research
Georgina Gal, Regulatory Affairs Manager, AbbVie, Hungary
Presentation at EIPG – BIPA Symposium “Clinical Trials Research” at the Faculty of Pharmacy, Medical University of Sofia, Sofia 2014.
Big Data and Clinical Research: Trends, Issues and ConsiderationsMerge eClinicalOS
Delivered by Zaher El-Assi, Merge Healthcare eClinical president, this presentation provided an overview of how researchers can leverage advanced information technology and strengthen their ability to meet the demands of increasingly complex studies and larger data sets – all while remaining compliant within an ever-changing regulatory landscape.
Presentation highlights included the following:
- Increasing cost, time and regulatory pressures are challenging clinical researchers to seek innovative methods and systems to capture and analyze clinical data.
- Recent policy changes at the FDA in the United States suggest a growing emphasis on quality over compliance with greater involvement the research process by patients and disease advocacy groups.
- There is a shift from population-based medicine to a more personalized approach fueled by advances in genomics and new technologies to monitor individual health.
- The four characteristics of Big Data are: volume, variety, velocity and veracity.
- The advent of Big Data in clinical research requires improved data collection and management systems, improved analytical tools and processes, and improvements in researchers’ ability to respond to rapidly changing circumstances in data outcomes.
- Mobile apps that enable researchers to manage critical study functions such as unblinding, randomization and inventory tracking will become more prevalent.
- The Big Data movement provides opportunities to:
- Strengthen health economics and outcomes research
- Target drugs at specific patient populations
- Accelerate drug and device development
- Improve patient recruitment and retention
- Clinical researchers will face more privacy, liability and technology challenges because of Big Data.
Zaher El-Assi is president of Merge eClinicalOS, a division of Merge Healthcare (NASDAQ: MRGE) and the fastest-growing software solution company in the clinical research industry. Prior to joining Merge Healthcare, Mr. El-Assi served as the vice president of Global Sales and Strategic Partnerships for Boston-based KIKA Clinical Solutions. At KIKA, he was responsible for establishing and developing global partnerships and building upon the company’s diverse client base. Among other achievements, Mr. El-Assi led the successful sale of KIKA Clinical Solutions to Merge Healthcare in 2010.
Access the webinar: http://goo.gl/p08pTz
These slides were presented in a webinar by Denodo in collaboration with BioStorage Technologies and Indiana Clinical and Translational Sciences Institute and Regenstrief Institute.
BioStorage Technologies, Inc., Indiana Clinical and Translational Sciences Institute, and Regenstrief Institute (CTSI) have joined Denodo to talk about the important role of technological advancements, such as data virtualization, in advancing biospecimen research.
By watching this webinar, you can gain insight into best practices around the integration of biospecimen and research data as well as technology solutions that provide consolidated views and rapid conversions of this data into valuable business insights. You will also learn how data virtualization can assist with the integration of data residing in heterogeneous repositories and can securely deliver aggregated data in real-time.
CCSN welcomed CADTH’s Patient Engagement Officer Sarah Berglas to hear more about the many aspects in which CADTH involves patients in its work.
Bill and Sarah walked through opportunities for patients and others to become involved in CADTH’s work, including:
- Providing patient input to CADTH’s pan-Canadian Oncology Drug Review (pCODR)
- Involving patients in CADTH’s assessments of medical devices, interventions, diagnostic tests, and procedures
- CADTH’s new Patient and Community Advisory Committee and
- CADTH’s newly published patient engagement framework.
There are other opportunities outside of the formal reviews, as well, and Sarah spoke further about what CADTH heard from its listening exercise with patient groups last fall.
Sarah also spoke about how patients will be involved in CADTH’s upcoming annual symposium on April 14-16 in Edmonton.
Maureen Smith also joined Bill and Sarah, sharing her experience convening public and patient members on Canadian HTA bodies to discuss our experiences, learn from experts and each other.
This is a must-see webinar for the engaged, the curious and the novice!
Prof Clive Badman OBE
Presentation at EIPG - Royal Pharmaceutical Society Scientific Symposium "Advances in Technology Impacting the Pharmaceutical Industry" at the University of Strathclyde, Glasgow 2015.
Aldo Rolfo, National Clinical Development Manager, Genesis Cancer Care, Austr...GenesisCareUK
A program that seeks to redefine best practice across the drivers of the GenesisCare business (Quality, Access and Efficiency) in order to deliver on their vision of “Innovating Healthcare. Transforming Lives.”
How Researchers Can Get Science Done Faster Using an R&D Services MarketplaceSC CTSI at USC and CHLA
Date: Feb 6, 2019
Topic: How Researchers Can Get Science Done Faster Using an R&D Services Marketplace
Speaker: Dr. Zev Wisotsky is a Senior Scientist and R&D Specialist at Science Exchange, where he assists researchers in connecting with the right R&D providers for their experiments and alerts his clients to newly available technologies. Dr. Wisotsky earned his PhD in neuroscience investigating taste detection using fruit fly and mosquito models at UC Riverside. He then completed postdoctoral research at Stanford studying the role of brain regions involved in fear memory and addiction through optogenetic silencing of different brain circuits.
Overview: Science Exchange is an open marketplace for scientific research that breaks down barriers to collaboration and innovation. The platform makes it easy for researchers to access more than 6,000 services from a network of over 2,500 qualified research providers. In this webinar, you will learn how researchers can use Science Exchange to access new technologies, get competitive quotes for specific projects, and order from any service provider under a single, pre-established contract. The presentation will also include examples of successful projects and collaborations, initiated on the Science Exchange platform, that have accelerated breakthrough
As of my last knowledge update in September 2021, the list of the top Contract Research Organizations (CROs) can vary depending on factors such as revenue, services offered, therapeutic areas of expertise, and global presence. The following list includes some of the prominent CROs based on their reputation, scale, and contributions to the clinical research industry:
IQVIA (formerly QuintilesIMS):
IQVIA is one of the largest CROs in the world, offering a wide range of services including clinical development, real-world evidence solutions, commercialization services, and consulting. They have a vast global network and expertise across various therapeutic areas.
PPD (Pharmaceutical Product Development):
PPD is known for its comprehensive clinical trial services, laboratory services, and real-world evidence solutions. They have a strong global presence and experience in managing trials of varying complexity.
Covance:
Covance, a subsidiary of LabCorp, is known for its extensive portfolio of drug development services including clinical development, central laboratory services, and market access solutions. They have experience in a broad range of therapeutic areas.
Syneos Health:
Syneos Health offers integrated solutions across clinical development, commercialization, and real-world evidence. They focus on helping clients navigate the entire drug development journey.
ICON:
ICON provides a variety of clinical research services, including consulting, clinical trial execution, laboratory services, and outcomes research. They have expertise in a wide array of therapeutic areas.
Parexel:
Parexel offers services ranging from clinical research and regulatory consulting to market access and commercialization. They are known for their global reach and innovative approach to clinical trials.
WuXi AppTec:
WuXi AppTec is a global company that provides a wide range of R&D services, including preclinical and clinical development, manufacturing, and regulatory services.
Medpace:
Medpace is known for its focused and customized approach to clinical trial management, particularly in the area of complex and specialized studies.
Celerion:
Celerion specializes in early-stage clinical research, with a focus on providing solutions for both small and large molecules.
Charles River Laboratories:
While Charles River Laboratories primarily focuses on preclinical research, they also offer a range of early-stage clinical development services.
Baptist Health- Engineering the Future of HealthcareLevi Shapiro
Presentation by Mark Coticchia, Chief Innovation Officer, Baptist Health, for mHealth Israel community, September, 2023. Baptist Health has internationally renowned centers of excellence in cancer, cardiovascular care, orthopedics and sports medicine, and neurosciences.
A not-for-profit organization supported by philanthropy and committed to its faith-based charitable mission of medical excellence, Recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World’s Most Ethical Companies.Innovation is paramount to health system’s performance and reputation.
Becker’s 2019 Advisory Board survey revealed innovation and technology ranked as the top priority among healthcare finance professionals - up from eighth in 2018. 90% healthcare/life science leaders agree that the pandemic will fundamentally change the way they do business, requiring new products, services, processes, and business models (McKinsey: Innovation Through Crisis Survey). Innovation has been proven to help health systems in many ways. A capability and culture of innovation accomplish numerous goals:
Innovation capability and culture improve the care and work environment. They enhance the reputation through recognition for discoveries made at and through Baptist Health. They aid in the recruitment and retention of top talent. And they help systems harness money that otherwise would be leaving the system – licensing revenues and investment returns and corporate research support and donor revenues. Successful Programs - Common Underpinnings. Innovation as a strategic, institutional priority
Program built on institutional assets and centers of excellence
Experienced, professional team
Technology development and sourcing, Dedicated, long term support. Doing healthcare innovation well at a large enterprise takes a highly specialized team and skill set. Collectively, they need to have deep knowledge of healthcare regulation, medical procedures, patient safety, business development, transactions, business law, innovation markets, entrepreneurship, venture capital, commercialization, tech transfer, organizational change management, and much more. Programs- services, technology management, corporate co-creation, global medical service lines and facilities; Focus on market opportunity vs. technology; Select & concentrate on winners; Operate as a business; Proactive in new company formation; Progress, milestones, preliminary results; Building New Innovation Pathways; Improving Treatment for Cancer Patients; Predicting & Preventing Heart Attacks; Improving Outcomes in Cardiac Care; Enhancing a Culture of Innovation at Baptist Health & South Florida; Cleerly, TriVentures, COTA; Innovation is paramount to health system’s performance and reputation.
Baptist Health has established an innovation function predicated on best practices and tailored to its assets and the opportunities extending from Miami’s economic growth
Harnessing the Power of Healthcare Data: Are We There YetHealth Catalyst
What can healthcare learn from Formula One racing? According to Dr. Sadiqa Mahmood, SVP of medical affairs and life sciences for Health Catalyst, race support teams leverage about 30TB of baseline data to create a digital twin of the car, track, and racer for simulation models that drive decisions at each race. Applied in the healthcare setting, a digital twin can help clinicians better understand each patient and their health conditions and circumstances in real time and make comprehensive, informed care decisions. But for the healthcare digital twin to happen, the industry must move away from data silos and towards a digital learning healthcare ecosystem.
Simon O'Byrne Presentation: Ignite Your City's Brand: Mess up Your Neighbourh...CityAge
The Innovation City: Simon O'Byrne Presentation: Ignite Your City's Brand: Mess up Your Neighbourhoods and Achieve Vibrancy, the Ultimate Civic Currency
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
4. Clinical Trials by Country:
Percent Change from 2005 to 2010
Japan
160%
Percentage of Change
180%
China
140%
Russian Confederation
120%
Poland
100%
Australia
CANADA
80%
60%
Argentina
40%
Germany
20%
0%
-20%
2
3
4
5
6
7
8
9
1
10
11
France
12
13
14
15
16
Brazil
India
Country by Rank from 1 to 16
5. Clinical Trial Sites by Country:
Percent Change from 2005 to 2010
250%
Japan
Percentage of Change
200%
India
China
150%
Russian Confederation
Argentina
100%
Poland
CANADA
50%
Brazil
Australia
South Africa
0%
1
2
3
4
5
6
7
8
9
-50%
10
11
United Kingdom
12
13
14
15
16
Spain
France
Country by Rank 1 to 16
9. Canada’s Strengths in Clinical
Trials
•
•
•
•
•
•
•
High reputation of researchers, organizations & outputs
Diverse population
Disease & population-specific networks & health charities
National progress on operational barriers
Interested public
Publically-funded healthcare & provincial funding for health
Federal & provincial leadership
10. Clinical Trials Summit 2011
• The first ever clinical trial steering committee meeting (Sep 2011)
• 150 experts from Government, Academia, Clinical Sites & Industry
• Topics critical to the Canadian clinical trial environment:
•
•
•
•
•
Ethics review process
Recruitment, patient retention & follow-up (administrative databases, e-records)
Cost structure
Administrative (contracts, standard operating procedures, education, training)
Future – what strengths can Canada develop that would make a difference in 5-10
years?
11. Clinical Trials Action Plan
http://www.acaho.org/?policy_2012
http://www.canadapharma.org/en/our-industry/clinical-trial-
12. Clinical Trials Action Plan
Vision: Canada to become a premier country globally for
conducting industry led clinical trials (CT)
Strategic Goals:
1. Establish short & longer term implementation capacity for this action
plan & coordination of other CT improvement activities
2. Improve business operations through better cost, quality, & speed of
clinical trial start-up times
3. Shape a positive future business environment & signal Canada’s interest
globally with information & incentives
13. What is Canadian Clinical Trials Asset
Map (CCTAM)?
Component of Strategic Goal # 3 of Action Plan
Web-based “living”, easily searchable, interactive
database of Canadian clinical research capabilities
Broad umbrella of stakeholders including Rx&D &
member companies, CIHR, DFAIT, Health Canada,
Industry Canada, ACAHO, BCCRIN, CTO, N2 and
independent research centers
14. CCTAM
Objectives
Improve capacity for both the academic &
commercial sectors to conduct clinical studies in
Canada
Position Canada globally as an attractive destination
for clinical trial investments
15. CCTAM: Design Principles
• Consider from view of both end user’s & the sites
• Ensure it meets evolving stakeholder
requirements
• Optimize scope & application of the tool
• Leverage & integrate experiences from existing
asset maps where possible to avoid duplication
of effort
16. Features of CCTAM
Bilingual
Comprehensive data set
Regular updates
Easy to search
No cost to contributors to use
17. Who Stands to Benefit?
Academic Research Sites
Independent Research Sites
Government
Industry
Academia
Canadians
18. Progress to Date
Key audiences & stakeholders identified & engaged
Existing asset maps audited to identify unmet needs &
potential data sources
British Columbia Clinical Research Infrastructure
Network’s (BCCRIN) Asset Map (http://
assets.bccrin.ca/ is being considered as a base
framework for CCTAM
Initial data points to be included identified
19. Progress to Date contd.
Work underway to enhance existing BCCRIN asset
map
Agreement in principle across RX&D member
companies to contribute data
Part I of communication strategy developed
21. A
collabora7ve
partnership
of
provincial
health
authori7es,
universi7es,
industry
associa7ons
and
funding
agencies.
Focused
on
transforming
the
clinical
research
landscape
in
BC.
A@ract
increased
investment
into
BC;
provide
improved
access
to
innova7ve
medicines
and
diagnos7cs.
Develop
first
in
class
research
processes
and
infrastructure
to
support
clinical
research
personnel
and
ac7vi7es.
This
network
has
the
poten7al
to
profoundly
alter
the
clinical
landscape
in
Canada
and
become
a
gold
standard
center
for
clinical
research
worldwide.
www.bccrin.ca
23. Online, searchable database with interactive elements
Information on clinical trials investigators, sites, research units, ethics
boards in BC
Captures BC biomedical, clinical, health services policy, population and
public health and medical device researchers
Includes academic, institutional and community/independent sites from
across the province
Industry standard: PHP, MySQL, Javascript. Allows for future updates
and extensions
www.bccrin.ca/
www.bccrin.ca
24. Summary
CCTAM initiative only possible due to the extraordinary
participation & commitment of groups & individuals across
industries, sectors & geographical locations in Canada
Significant progress over the past 18 months in developing the
CCTAM
Once complete, CCTAM will be a comprehensive one-stop tool for
both local & global entities considering Canada as a site for
clinical research
CCTAM will continue to evolve & develop true to its living tool
concept